Drug intelligence / Profile preview

Ocutears Aloe+

Development stage: Unknown
Lead developer: Santen Pharmaceutical
Modality: Small Molecules
Administration: Ophthalmic

Overview

Ocutears Aloe+ is a preservative-free ophthalmic solution containing 0.2% cross-linked hyaluronic acid and 0.1% aloe vera. It is designed to treat dry eye disease (DED) and ocular surface discomfort, particularly following ophthalmic surgeries like cataract surgery. The cross-linked hyaluronic acid provides enhanced viscoelasticity and longer residence time on the ocular surface compared to linear hyaluronic acid, while aloe vera offers soothing and anti-inflammatory properties. The product is developed and marketed by Santen and is being evaluated in clinical studies by institutions like the Chinese University of Hong Kong.

Brand names: Ocutears Aloe+
Other names: Ocutears Aloe+0.2% cross-linked hyaluronic acid + 0.1% aloe vera

Beyond the preview

Go deeper on Ocutears Aloe+.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocutears Aloe+.

Explore the full profile